LAS VEGAS, Oct. 12, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that its Board of Directors will conduct a process to explore and evaluate strategic alternatives for Cord Blood America to enhance shareholder value.
Cord Blood America has not set a timetable for completion of the evaluation process or made a decision to pursue any particular transaction or other alternative, and there can be no assurance that any transaction or other alternative will be pursued or completed.
Cord Blood America does not intend to comment further regarding the evaluation of possible strategic alternatives, unless a specific transaction or process is concluded, or it otherwise deems further disclosure is appropriate or required.
About Cord Blood America
Cord Blood America is the parent company of CorCell, Companies, Inc., which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul Knopick
E & E Communications
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
|SOURCE Cord Blood America, Inc.|
Copyright©2010 PR Newswire.
All rights reserved